Related Experiment Videos
Mitral valve prolapse in hyperthyroidism of two different origins
Insights
Graves' disease, a form of hyperthyroidism, is significantly linked to mitral valve prolapse. However, hyperthyroidism overall and toxic nodular goitre did not show a significant association with this heart condition.
Area of Science:
- Cardiology
- Endocrinology
- Thyroid Disorders
Background:
- Hyperthyroidism, particularly Graves' disease, can affect cardiovascular function.
- Mitral valve prolapse (MVP) is a common cardiac condition with varying prevalence.
- The relationship between hyperthyroidism and MVP requires further investigation.
Purpose of the Study:
- To determine the prevalence of mitral valve prolapse in patients with hyperthyroidism.
- To assess the prevalence of hyperthyroidism in patients with mitral valve prolapse.
- To compare the prevalence of MVP in Graves' disease and toxic nodular goitre patients with a control group.
Main Methods:
- Cross-sectional study comparing patient groups and a control cohort.
- Inclusion criteria: 126 hyperthyroid patients (Graves' disease or toxic nodular goitre) and 64 MVP patients.
- Control group: 111 asymptomatic healthy subjects.
Main Results:
- Overall prevalence of MVP in hyperthyroid patients (9.5%) was not significantly higher than in controls (5.4%).
- Prevalence of MVP in toxic nodular goitre patients was similar to controls.
- Significantly higher prevalence of MVP was observed in Graves' disease patients (16.3%) compared to controls (5.4%).
- Only one MVP patient presented with hyperthyroidism.
Conclusions:
- Graves' disease is associated with a significantly increased prevalence of mitral valve prolapse.
- Hyperthyroidism, in general, and toxic nodular goitre specifically, do not show a significant association with mitral valve prolapse.
- Further research is warranted to elucidate the specific mechanisms linking Graves' disease and MVP.
Abstract:
The prevalence of mitral valve prolapse was investigated in 126 patients with hyperthyroidism due to Graves' disease or toxic nodular goitre and that of hyperthyroidism in 64 patients with mitral valve prolapse. One hundred and eleven asymptomatic healthy subjects comprised a control group. The patients with hyperthyroidism were divided into those with Graves' disease and those with toxic nodular goitre. Of the group as whole, 12 (9.5%) patients had mitral valve prolapse compared with six (5.4%) in the control group, but the difference was not statistically significant. The prevalence of mitral valve prolapse in the patients with toxic goitre was also not significantly different from that in the controls. When the prevalence in the group with Graves' disease was compared with that in the control group (16.3% vs 5.4%) the difference was significant. Only one patient with mitral valve prolapse had hyperthyroidism.